" /> Autologous CD5KO Anti-CD5 CAR 4-1BB-expressing T-lymphocytes and Autologous CD5KO T-lymphocytes - CISMeF





Preferred Label : Autologous CD5KO Anti-CD5 CAR 4-1BB-expressing T-lymphocytes and Autologous CD5KO T-lymphocytes;

NCIt synonyms : Autologous CD5-deleted Anti-CD5 CAR-T Cells and CD5-deleted T-cells; tologous CD5KO Anti-CD5 CAR 4-1BB-expressing T-lymphocytes Plus Autologous CD5KO T-lymphocytes; Autologous CD5KO CART5 Cells and CD5KO Normal Untransduced T-cells; Autologous Senza5 (R) CART5 Cells; CD5 Knockout Cells and CD5KO-CART5 Cells;

NCIt definition : A dual-population preparation of autologous T-lymphocytes in which the tumor-associated antigen (TAA) CD5 is knocked out (CD5KO) and is genetically modified to express a chimeric antigen receptor (CAR) specific for CD5 and coupled to the co-stimulatory molecule 4-1BB (CD137), and autologous CD5KO normal untransduced T-lymphocytes, with potential immunomodulating and antineoplastic activities. Upon administration of autologous CD5KO anti-CD5 CAR 4-1BB-expressing T-lymphocytes and autologous CD5KO T-lymphocytes, the autologous CD5KO anti-CD5 CAR 4-1BB-expressing T-lymphocytes specifically recognize and kill CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells and overexpressed on various B- and T-cell malignancies. CD5 KO in the CART5 cells prevents CART fratricide and enhances CAR-T cell function. The CD5KO normal T-cells allow for T-cell reconstitution and may mitigate T-cell toxicity.;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.